ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.
Open access · goldAbstract read
In one paragraph
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 3 citations in OpenAlex.
- Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications.Vaccines · 2026Review
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses.Journal of nanobiotechnology · 2024Review
- Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 12 institutions in 4 countries.
Rodrigo Lázaro-GorinesCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain.ORCID 0000-0002-6885-3486
Patricia PérezDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28049, Spain.ORCID 0000-0001-8983-6784
Ignacio Heras-MurilloImmunobiology lab, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0002-8797-8786
Irene Adán-BarrientosImmunobiology lab, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0003-4442-9645
Guillermo AlbericioDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28049, Spain.ORCID 0000-0003-0190-4848
David AstorganoDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28049, Spain.ORCID 0000-0002-2969-1840
Sara FloresDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28049, Spain.
Joanna LuczkowiakVirology and HIV/AIDS Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, 28041, Spain.ORCID 0000-0001-6950-9372
Nuria LabiodVirology and HIV/AIDS Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, 28041, Spain.ORCID 0000-0001-7297-1162
Seandean L HarwoodDepartment of Molecular Biology and Genetics - Protein Science, Aarhus University, Aarhus, 80000, Denmark.ORCID 0000-0003-4654-8832
Alejandro Segura-TudelaCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain.ORCID 0000-0002-5506-0153
Laura Rubio-PérezCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain.
Yudhi NugrahaProtein Crystallography Unit, Structural Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, 28029, Spain.ORCID 0000-0003-1186-4093
Xiaoran ShangInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.ORCID 0000-0002-3986-4557
Yuxing LiInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.ORCID 0000-0001-9785-2960
Carlos AlfonsoCentro de Investigaciones Biológicas Margarita Salas (CIB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28040, Spain.ORCID 0000-0001-7165-4800
Kaylin A AdipietroThe Center for Biomolecular Therapeutics, Rockville, MD, 20850, USA.
Dinendra L AbeyawardhaneInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.ORCID 0000-0003-3002-7792
Rocío NavarroDepartment of Antibody Engineering, Leadartis SL, Tres Cantos, Madrid, 28002, Spain.ORCID 0000-0002-0083-7711
Marta CompteDepartment of Antibody Engineering, Leadartis SL, Tres Cantos, Madrid, 28002, Spain.ORCID 0000-0002-7138-9266
Wenbo YuInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.
Alexander D MacKerellInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.
Laura SanzMolecular Immunology Unit, Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, 28220, Spain.ORCID 0000-0002-3119-3218
David J WeberInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.ORCID 0000-0002-8824-1110
Francisco J BlancoCentro de Investigaciones Biológicas Margarita Salas (CIB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28040, Spain.ORCID 0000-0003-2545-4319
Mariano EstebanDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28049, Spain.ORCID 0000-0003-0846-2827
Edwin PozharskiInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.ORCID 0000-0001-7012-5376
Raquel Godoy-RuizInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, 20850, USA.ORCID 0000-0003-4569-0781
Inés G MuñozProtein Crystallography Unit, Structural Biology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, 28029, Spain.ORCID 0000-0001-6732-4059
Rafael DelgadoVirology and HIV/AIDS Group, Instituto de Investigación Sanitaria 12 de Octubre (imas12), Madrid, 28041, Spain.ORCID 0000-0002-6912-4736
David SanchoImmunobiology lab, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, 28029, Spain.ORCID 0000-0003-2890-3984
Juan García-ArriazaDepartment of Molecular and Cellular Biology, Centro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), Madrid, 28049, Spain.ORCID 0000-0002-5167-5724
Luis Álvarez-VallinaCancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain.ORCID 0000-0003-3053-6757
Consejo Superior de Investigaciones Científicas · ESUniversity of Maryland, Baltimore · USResearch Institute Hospital 12 de Octubre · ESSpanish National Centre for Cardiovascular Research · ESUnited Therapeutics (United States) · USSpanish National Cancer Research Centre · ESUnidades Centrales Científico-Técnicas · ESUniversidad Francisco de Vitoria · ESAarhus University · DKHospital Universitario Puerta de Hierro Majadahonda · ESResearch Institute for Bioscience and Biotechnology · NPUniversidad Complutense de Madrid · ES
Funding
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4MHigh-resolution definition of B cell responses to HIV Env for immunogen designR01AI102766 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LI, YUXING · 2013 to 2024
$6.6MMacromolecular Conformational HeterogeneityR35GM131710 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ALEXANDER D MACKERELL · 2019 to 2026
$6.2MNext Generation Broadly Neutralizing Antibodies to Clear HIV-1 ReservoirR01AI136756 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LI, QINGSHENG, LI, YUXING · 2019 to 2023
$3.9MEvolution of anti-filovirus B cell responses and mechanisms of protectionR01AI126587 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, LI, YUXING · 2017 to 2021
$3.7MAnti-flavivirus B cell response analysis to aid vaccine designR01AI175439 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Yuxing Li · 2023 to 2026
$3.1MMonoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoproteinR41AI147929 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, LI, YUXING · 2019 to 2020
$600kNIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI102766NIAID NIH HHS R01 AI126587NIAID NIH HHS R01 AI136756NIAID NIH HHS R01 AI175439NIAID NIH HHS R41 AI147929NIGMS NIH HHS R35 GM131710
Abstract
Administration of neutralizing antibodies (nAbs) has proved to be effective by providing immediate protection against SARS-CoV-2. However, dual strategies combining virus neutralization and immune response stimulation to enhance specific cytotoxic T cell responses, such as dendritic cell (DC) cross-priming, represent a promising field but have not yet been explored. Here, a broadly nAb, TN
Indexed as
Antibodies, NeutralizingCOVID-19AnimalsCross-PrimingDendritic CellsMiceSARS-CoV-2T-Lymphocytes, CytotoxicAntibodies, Neutralizingbispecific trimerbodycross-primingCTL responsesdendritic cellsneutralizing antibodySARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.